Logical Biological has settled into larger, upgraded laboratory space at Discovery Park, marking its third move within the science and innovation campus.
Naobios and Sumagen Canada Inc, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, announced the production of the HIV-1 vaccine candidate at bench scale.
AstraZeneca’s drug Fasenra (benralizumab) has been approved in the European Union as an additional treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA).
CluePoints announced that Richard Young has been appointed as its new chief strategy officer who will ensure CluePoints’ continued growth and development as a provider of integrated data review software.
Takeda announced positive interim results from a Phase 3-enabling proof-of-concept study for mezagitamab (TAK-079), an anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN).
Coronado Research announced that Professor Jennifer Visser-Rogers has been appointed as chief scientific officer, bringing with her a broad portfolio of scientific achievement across academia and industry.
ApiJect announced it has been awarded an initial grant of $425,000 from the Bill & Melinda Gates Foundation to develop low-cost blow-fill-seal prefilled injection devices to enhance access in Low- and Middle-Income Countries (LMICs).
The FDA has expanded approval for Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, to include adults aged 18–59 years who are at higher risk of lower respiratory tract disease from the virus due to chronic conditions.
BirchBioMed announced the authorisation from Health Canada to conduct its Phase II/III randomised clinical trial of a naturally based compound, FS2, at multiple centres of expertise throughout Canada.
Avantor and NIBRT have formed a new partnership to supply advanced Masterflex equipment, essential products and expert training to foster innovations in biopharma manufacturing.
Bioptimus announced that its H-optimus-0 foundation model is now integrated into Proscia’s Concentriq Embeddings, enabling data scientists and researchers in pathology and life sciences to achieve breakthroughs in AI development.
